Source: European Biotechnology

Rewind Therapeutics: Rewind Therapeutics extends Series A financing

Read full article »

Rewind Therapeutics's Competitors | Rewind Therapeutics's News | Rewind Therapeutics's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Anja Harmeier

CEO Approval Rating

90/100

Rewind Therapeutics is a Belgium-based biotechnology company that researches and develops remyelinating therapies for the treatment of multiple sclerosis.